摘要
目的观察多发性骨髓瘤(MM)患者经标准BD方案(硼替佐米+地塞米松)诱导序贯自体造血干细胞移植(auto-HSCT)和移植后维持治疗的临床效果。方法回顾性分析2011年1月至2017年8月于郑州大学第一附属医院造血干细胞移植中心行BD方案序贯auto-HSCT及维持治疗的38例MM患者的临床资料。结果38例MM患者中位随访时间为21个月(9~64个月),3 a总体生存(OS)率为67.4%,3 a无进展生存(PFS)率为54.3%。auto-HSCT后应用“硼替佐米+沙利度胺”维持治疗组3 a PFS率高于单用沙利度胺维持治疗组(57.5%比49.4%,P<0.05)。应用“硼替佐米+沙利度胺”维持治疗组3 a OS率与单用沙利度胺维持治疗组差异无统计学意义(80.0%比61.3%,P>0.05)。结论BD方案序贯auto-HSCT是治疗MM的有效方法,移植后应用“硼替佐米+沙利度胺”进行维持治疗可进一步延长MM患者PFS。
Objective To observe the therapeutic effect of sequential autologous hematopoietic stem cell transplantation(auto-HSCT)induced by BD(bortezomib+dexamethasone)regimen and post-transplantation maintenance therapy in multiple myeloma(MM)patients.Methods The clinical data of 38 MM patients received sequential auto-HSCT induced by BD regimen and post-transplantation maintenance therapy at the Hematopoietic Stem Cell Transplantation Center in the First Affiliated Hospital of Zhengzhou University from January 2011 to August 2017 were retrospectively analyzed.Results The median follow-up time for 38 MM patients was 21 months(9-64 months),the 3-year overall survival(OS)rate was 67.4%,the 3-year progression-free survival(PFS)rate was 54.3%.The 3-year PFS rate of“bortezomib+thalidomide”maintenance treatment group was significantly higher than that of thalidomide group(57.5%versus 49.4%,P<0.05).There was no significant difference in 3-year OS rate between the“bortezomib+thalidomide”maintenance treatment group and the thalidomide maintenance treatment group(80.0%versus 61.3%,P>0.05).Conclusions Auto-HSCT induced by BD regimen is an effective treatment for MM patients.After auto-HSCT,“bortezomib+thalidomide”maintenance treatment could further extend PFS for MM patients.
作者
闫苒
万鼎铭
谢新生
曹伟杰
王萌
张素平
张然
YAN Ran;WAN Ding-ming;XIE Xin-sheng;CAO Wei-Jie;WANG Meng;ZHANG Su-ping;ZHANG Ran(Hematopoietic Stem Cell Transplantation Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《河南医学研究》
CAS
2019年第18期3272-3275,共4页
Henan Medical Research
关键词
多发性骨髓瘤
硼替佐米
自体造血干细胞移植
维持治疗
multiple myeloma
bortezomib
autologous hematopoietic stem cell transplantation
maintenance treatment
